![Vassiliki KARANTZA | Clinical Director | Merck & Co., Whitehouse Station | MSD | Department of Oncology Vassiliki KARANTZA | Clinical Director | Merck & Co., Whitehouse Station | MSD | Department of Oncology](https://www.researchgate.net/publication/337962528/figure/fig3/AS:836929050386432@1576550843126/Graphical-representations-of-objective-response-rates-ORRs-for-a-trials-of_Q320.jpg)
Vassiliki KARANTZA | Clinical Director | Merck & Co., Whitehouse Station | MSD | Department of Oncology
![Oliver BOGLER | Professor (Full) | PhD | University of Texas MD Anderson Cancer Center, Texas | MD Anderson | Department of NeuroSurgery Oliver BOGLER | Professor (Full) | PhD | University of Texas MD Anderson Cancer Center, Texas | MD Anderson | Department of NeuroSurgery](https://www.researchgate.net/publication/330298395/figure/fig2/AS:713721433309185@1547175858442/Maximum-dose-was-reduced-using-automatic-beam-weight-optimization-The-maximum-dose_Q320.jpg)
Oliver BOGLER | Professor (Full) | PhD | University of Texas MD Anderson Cancer Center, Texas | MD Anderson | Department of NeuroSurgery
![Vassiliki KARANTZA | Clinical Director | Merck & Co., Whitehouse Station | MSD | Department of Oncology Vassiliki KARANTZA | Clinical Director | Merck & Co., Whitehouse Station | MSD | Department of Oncology](https://i1.rgstatic.net/ii/profile.image/1011183721144321-1618096394897_Q128/Jing-Zhao-99.jpg)
Vassiliki KARANTZA | Clinical Director | Merck & Co., Whitehouse Station | MSD | Department of Oncology
![Adoption of Hypofractionated Radiation Therapy for Breast Cancer After Publication of Randomized Trials | Request PDF Adoption of Hypofractionated Radiation Therapy for Breast Cancer After Publication of Randomized Trials | Request PDF](https://i1.rgstatic.net/ii/profile.image/958989760204803-1605652384490_Q64/Jean-Philippe-Pignol-2.jpg)
Adoption of Hypofractionated Radiation Therapy for Breast Cancer After Publication of Randomized Trials | Request PDF
![Adoption of Hypofractionated Radiation Therapy for Breast Cancer After Publication of Randomized Trials | Request PDF Adoption of Hypofractionated Radiation Therapy for Breast Cancer After Publication of Randomized Trials | Request PDF](https://i1.rgstatic.net/ii/profile.image/1012822234374150-1618487046512_Q64/V-Batumalai.jpg)
Adoption of Hypofractionated Radiation Therapy for Breast Cancer After Publication of Randomized Trials | Request PDF
![Primary spermatic cord tumors: Disease characteristics, prognostic factors, and treatment outcomes | Request PDF Primary spermatic cord tumors: Disease characteristics, prognostic factors, and treatment outcomes | Request PDF](https://i1.rgstatic.net/ii/profile.image/970534665863168-1608404904294_Q64/Raquel-Sopena-Sutil.jpg)
Primary spermatic cord tumors: Disease characteristics, prognostic factors, and treatment outcomes | Request PDF
![Adoption of Hypofractionated Radiation Therapy for Breast Cancer After Publication of Randomized Trials | Request PDF Adoption of Hypofractionated Radiation Therapy for Breast Cancer After Publication of Randomized Trials | Request PDF](https://i1.rgstatic.net/ii/profile.image/1028072774066176-1622123058164_Q64/Ankur-Patel-38.jpg)
Adoption of Hypofractionated Radiation Therapy for Breast Cancer After Publication of Randomized Trials | Request PDF
![Adoption of Hypofractionated Radiation Therapy for Breast Cancer After Publication of Randomized Trials | Request PDF Adoption of Hypofractionated Radiation Therapy for Breast Cancer After Publication of Randomized Trials | Request PDF](https://i1.rgstatic.net/ii/profile.image/966473229008899-1607436582351_Q64/Ioannis-Georgakopoulos-2.jpg)
Adoption of Hypofractionated Radiation Therapy for Breast Cancer After Publication of Randomized Trials | Request PDF
![Oliver BOGLER | Professor (Full) | PhD | University of Texas MD Anderson Cancer Center, Texas | MD Anderson | Department of NeuroSurgery Oliver BOGLER | Professor (Full) | PhD | University of Texas MD Anderson Cancer Center, Texas | MD Anderson | Department of NeuroSurgery](https://www.researchgate.net/profile/Ioannis-Nezis/publication/44676885/figure/fig3/AS:271111430602769@1441649410423/CIN85Dex2-knockout-mice-display-metabolic-and-behavioural-phenotypes-A-CIN85Dex2_Q320.jpg)
Oliver BOGLER | Professor (Full) | PhD | University of Texas MD Anderson Cancer Center, Texas | MD Anderson | Department of NeuroSurgery
![Vassiliki KARANTZA | Clinical Director | Merck & Co., Whitehouse Station | MSD | Department of Oncology Vassiliki KARANTZA | Clinical Director | Merck & Co., Whitehouse Station | MSD | Department of Oncology](https://www.researchgate.net/publication/351566802/figure/tbl1/AS:1023185684275202@1620957885796/5-Year-Disease-Free-and-Overall-Survival_Q320.jpg)
Vassiliki KARANTZA | Clinical Director | Merck & Co., Whitehouse Station | MSD | Department of Oncology
![Oliver BOGLER | Professor (Full) | PhD | University of Texas MD Anderson Cancer Center, Texas | MD Anderson | Department of NeuroSurgery Oliver BOGLER | Professor (Full) | PhD | University of Texas MD Anderson Cancer Center, Texas | MD Anderson | Department of NeuroSurgery](https://www.researchgate.net/publication/330298395/figure/fig3/AS:713721433309186@1547175858465/Patient-plans-with-high-maximum-doses-experience-a-substantial-reduction-in-the-maximum_Q320.jpg)
Oliver BOGLER | Professor (Full) | PhD | University of Texas MD Anderson Cancer Center, Texas | MD Anderson | Department of NeuroSurgery
![Vassiliki KARANTZA | Clinical Director | Merck & Co., Whitehouse Station | MSD | Department of Oncology Vassiliki KARANTZA | Clinical Director | Merck & Co., Whitehouse Station | MSD | Department of Oncology](https://www.researchgate.net/publication/351566802/figure/tbl2/AS:1023185684291584@1620957885816/Univariate-Analyses-of-Disease-Free-Survival-for-Identication-of-Potential-Prognostic_Q320.jpg)
Vassiliki KARANTZA | Clinical Director | Merck & Co., Whitehouse Station | MSD | Department of Oncology
![Hepatocellular carcinoma in children: Epidemiology and the impact of regional lymphadenectomy on surgical outcomes | Request PDF Hepatocellular carcinoma in children: Epidemiology and the impact of regional lymphadenectomy on surgical outcomes | Request PDF](https://i1.rgstatic.net/ii/profile.image/962133550440448-1606401922057_Q64/Joseph-Kim-34.jpg)
Hepatocellular carcinoma in children: Epidemiology and the impact of regional lymphadenectomy on surgical outcomes | Request PDF
![Breast Cancer in HIV-Positive Women: A Report of Four Cases and Review of the Literature | Request PDF Breast Cancer in HIV-Positive Women: A Report of Four Cases and Review of the Literature | Request PDF](https://i1.rgstatic.net/ii/profile.image/279949027102728-1443756457226_Q64/Maria-De-La-Calle-4.jpg)
Breast Cancer in HIV-Positive Women: A Report of Four Cases and Review of the Literature | Request PDF
![Oliver BOGLER | Professor (Full) | PhD | University of Texas MD Anderson Cancer Center, Texas | MD Anderson | Department of NeuroSurgery Oliver BOGLER | Professor (Full) | PhD | University of Texas MD Anderson Cancer Center, Texas | MD Anderson | Department of NeuroSurgery](https://www.researchgate.net/publication/330298395/figure/fig1/AS:713721433313283@1547175858387/Automatically-created-treatment-fields-Beams-eye-view-of-the-A-anteroposterior-AP_Q320.jpg)
Oliver BOGLER | Professor (Full) | PhD | University of Texas MD Anderson Cancer Center, Texas | MD Anderson | Department of NeuroSurgery
![Vassiliki KARANTZA | Clinical Director | Merck & Co., Whitehouse Station | MSD | Department of Oncology Vassiliki KARANTZA | Clinical Director | Merck & Co., Whitehouse Station | MSD | Department of Oncology](https://www.researchgate.net/publication/337962528/figure/fig2/AS:836929050390529@1576550843107/Historical-objective-response-rate-ORR-with-chemotherapy-in-2L-mTNBC-Meta-analysis-of_Q320.jpg)
Vassiliki KARANTZA | Clinical Director | Merck & Co., Whitehouse Station | MSD | Department of Oncology
![Oliver BOGLER | Professor (Full) | PhD | University of Texas MD Anderson Cancer Center, Texas | MD Anderson | Department of NeuroSurgery Oliver BOGLER | Professor (Full) | PhD | University of Texas MD Anderson Cancer Center, Texas | MD Anderson | Department of NeuroSurgery](https://www.researchgate.net/profile/Ioannis-Nezis/publication/44676885/figure/fig2/AS:271110235226121@1441649125244/CIN85-is-highly-expressed-in-neurons-in-which-it-localizes-to-post-synaptic-sites-A_Q320.jpg)
Oliver BOGLER | Professor (Full) | PhD | University of Texas MD Anderson Cancer Center, Texas | MD Anderson | Department of NeuroSurgery
![Fusion genes with ALK as recurrent partner in ependymoma-like gliomas: A new brain tumor entity? | Request PDF Fusion genes with ALK as recurrent partner in ependymoma-like gliomas: A new brain tumor entity? | Request PDF](https://i1.rgstatic.net/ii/profile.image/989047140929539-1612818622032_Q64/Despoina-Ntenekou.jpg)
Fusion genes with ALK as recurrent partner in ependymoma-like gliomas: A new brain tumor entity? | Request PDF
![Primary spermatic cord tumors: Disease characteristics, prognostic factors, and treatment outcomes | Request PDF Primary spermatic cord tumors: Disease characteristics, prognostic factors, and treatment outcomes | Request PDF](https://i1.rgstatic.net/ii/profile.image/1009387174895617-1617668064917_Q64/Saloua-Daoudi.jpg)